Abbott has officially launched its latest-generation MitraClip G5 and TriClip G5 systems, advancing minimally invasive treatment options for patients with heart valve disease.
Sandra Lesenfants, Senior Vice President of Abbott’s Structural Heart Division, announced the release on LinkedIn, stating, “I am proud to share that Abbott’s MitraClip and TriClip G5 Systems are now available. This innovative system reflects the dedication of our Structural Heart team to deliver quality solutions that address both physician and patient needs.”
The launch follows a major milestone: the Centers for Medicare and Medicaid Services (CMS) recently issued a National Coverage Determination (NCD) for tricuspid transcatheter edge-to-edge repair (T-TEER), including coverage of Abbott’s TriClip system for tricuspid regurgitation (TR). This makes TriClip a viable option for patients who are not eligible for surgery and continue to experience TR symptoms despite medical therapy.
TriClip is delivered via a vein in the leg and functions by clipping the valve leaflets together, improving valve function without the need for open-heart surgery.
Meanwhile, the MitraClip G5 continues to offer a percutaneous solution for patients with mitral regurgitation (MR), enabling the reduction of significant MR symptoms with a catheter-based approach.
Both the MitraClip G5 and TriClip G5 systems are designed for easy handling, precise positioning, and intuitive deployment. They have received FDA approval and CE mark, offering improved usability for transcatheter edge-to-edge repair (TEER) procedures.
Abbott also highlights the use of nitinol, a shape-memory alloy, in its heart clip implants to enhance grip and flexibility via frictional elements and leaf springs.
In related news, Dr. Ethan Korngold, CMO of Abbott Vascular, will present on the role of AI in Abbott’s cardiovascular innovations at DeviceTalks West 2025, scheduled for October 15–16 in Santa Clara, California.